Find clinical trials for Leukemia in Berlin, BE
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Leukemia trials near Berlin, BE, DEU:
inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase 1. In Phase 2, assessment of ziftomenib wil...
Phase 1, Phase 2
Berlin, Germany and 51 other locations
with low-dose cytarabine (LDAC) improves overall survival (OS) versus LDAC and placebo, in treatment-naïve patients with acute myeloid leukemia...
Phase 3
Berlin, Berlin, Germany and 108 other locations
in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic syndromes with increased blasts grade 2...
Phase 1, Phase 2
Berlin, Berlin, Germany and 33 other locations
The purpose of this study is to characterize the efficacy of ponatinib administered in 3 starting doses (45 mg, 30 mg, and 15 mg daily) in participan...
Phase 2
Berlin, Germany and 85 other locations
The study aims to evaluate the safety, efficacy, and tolerability of subcutaneous (SC) blinatumomab for treatment of Acute Lymphoblastic Leukemia...
Phase 1, Phase 2
Berlin, Germany and 42 other locations
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess retr...
Phase 2
Berlin, Germany and 49 other locations
of asciminib versus nilotinib for the treatment of newly diagnosed, previously untreated patients with Positive Chronic Myelogenous Leukemia...
Phase 3
Berlin, Germany and 120 other locations
of the combinations of AG-120 with azacitidine and AG-221 with azacitidine versus with azacitidine alone in participants with acute myeloid leukemia...
Phase 1, Phase 2
Berlin, Germany and 48 other locations
clinical evaluation of ELVN-001 in patients with chronic myeloid leukemia with and without T315I mutations in patients who are relapsed, ref...
Phase 1
Berlin, Germany and 28 other locations
The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of bleximenib in combination with AML directed therapies (...
Phase 1
Berlin, Germany and 30 other locations
Clinical trials
Research sites
Resources
Legal